212 related articles for article (PubMed ID: 24069322)
41. Novel insights into genetics and clinics of the HNF1A-MODY.
Valkovicova T; Skopkova M; Stanik J; Gasperikova D
Endocr Regul; 2019 Apr; 53(2):110-134. PubMed ID: 31517624
[TBL] [Abstract][Full Text] [Related]
42. Mexican Carriers of the
Martagón AJ; Bello-Chavolla OY; Arellano-Campos O; Almeda-Valdés P; Walford GA; Cruz-Bautista I; Gómez-Velasco DV; Mehta R; Muñoz-Hernández L; Sevilla-González M; Viveros-Ruiz TL; Ordoñez-Sánchez ML; Rodríguez-Guillen R; Florez JC; Tusié-Luna MT; Aguilar-Salinas CA;
Diabetes Care; 2018 Aug; 41(8):1726-1731. PubMed ID: 29844095
[TBL] [Abstract][Full Text] [Related]
43. Can complement factors 5 and 8 and transthyretin be used as biomarkers for MODY 1 (HNF4A-MODY) and MODY 3 (HNF1A-MODY)?
Karlsson E; Shaat N; Groop L
Diabet Med; 2008 Jul; 25(7):788-91. PubMed ID: 18513302
[TBL] [Abstract][Full Text] [Related]
44. Primary hepatocellular adenoma due to biallelic HNF1A mutations and its co-occurrence with MODY 3: case-report and review of the literature.
Fu J; Wang T; Zhai X; Xiao X
Endocrine; 2020 Mar; 67(3):544-551. PubMed ID: 31754975
[TBL] [Abstract][Full Text] [Related]
45. Functional Analyses of HNF1A-MODY Variants Refine the Interpretation of Identified Sequence Variants.
Malikova J; Kaci A; Dusatkova P; Aukrust I; Torsvik J; Vesela K; Kankova PD; Njølstad PR; Pruhova S; Bjørkhaug L
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 32017842
[TBL] [Abstract][Full Text] [Related]
46. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database.
Schober E; Rami B; Grabert M; Thon A; Kapellen T; Reinehr T; Holl RW;
Diabet Med; 2009 May; 26(5):466-73. PubMed ID: 19646184
[TBL] [Abstract][Full Text] [Related]
47. Altered cortisol metabolism in individuals with HNF1A-MODY.
Juszczak A; Gilligan LC; Hughes BA; Hassan-Smith ZK; McCarthy MI; Arlt W; Tomlinson JW; Owen KR
Clin Endocrinol (Oxf); 2020 Sep; 93(3):269-279. PubMed ID: 32395877
[TBL] [Abstract][Full Text] [Related]
48. Comparison of Glomerular Filtration Rate Estimation from Serum Creatinine and Cystatin C in HNF1A-MODY and Other Types of Diabetes.
Szopa M; Kapusta M; Matejko B; Klupa T; Koblik T; Kiec-Wilk B; Borowiec M; Malecki MT
J Diabetes Res; 2015; 2015():183094. PubMed ID: 26347889
[TBL] [Abstract][Full Text] [Related]
49. Genetic and clinical characteristics of patients with HNF1A gene variations from the German-Austrian DPV database.
Awa WL; Thon A; Raile K; Grulich-Henn J; Meissner T; Schober E; Holl RW;
Eur J Endocrinol; 2011 Apr; 164(4):513-20. PubMed ID: 21224407
[TBL] [Abstract][Full Text] [Related]
50. Divergent phenotypes in siblings with identical novel mutations in the HNF-1α gene leading to maturity onset diabetes of the young type 3.
Knebel B; Mack S; Haas J; Herman-Friede MK; Lange S; Schubert O; Kotzka J; Muller-Wieland D
BMC Med Genet; 2016 May; 17(1):36. PubMed ID: 27142837
[TBL] [Abstract][Full Text] [Related]
51. Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha and 4 alpha in maturity-onset diabetes of the young and hyperinsulinemic hypoglycemia.
Colclough K; Bellanne-Chantelot C; Saint-Martin C; Flanagan SE; Ellard S
Hum Mutat; 2013 May; 34(5):669-85. PubMed ID: 23348805
[TBL] [Abstract][Full Text] [Related]
52. Clinical application of ACMG-AMP guidelines in HNF1A and GCK variants in a cohort of MODY families.
Santana LS; Caetano LA; Costa-Riquetto AD; Quedas EPS; Nery M; Collett-Solberg P; Boguszewski MCS; Vendramini MF; Crisostomo LG; Floh FO; Zarabia ZI; Kohara SK; Guastapaglia L; Passone CGB; Sewaybricker LE; Jorge AAL; Teles MG
Clin Genet; 2017 Oct; 92(4):388-396. PubMed ID: 28170077
[TBL] [Abstract][Full Text] [Related]
53. Cystatin C is not a good candidate biomarker for HNF1A-MODY.
Nowak N; Szopa M; Thanabalasingham G; McDonald TJ; Colclough K; Skupien J; James TJ; Kiec-Wilk B; Kozek E; Mlynarski W; Hattersley AT; Owen KR; Malecki MT
Acta Diabetol; 2013 Oct; 50(5):815-20. PubMed ID: 22350134
[TBL] [Abstract][Full Text] [Related]
54. An alternative approach using hs-CRP levels and age of onset in diagnostics of HNF1A-MODY.
Kickova T; Skopkova M; Dobiasova Z; Lackova G; Belicova Z; Schenkova K; Stanik J; Gasperikova D
Diabet Med; 2024 May; 41(5):e15265. PubMed ID: 38093550
[TBL] [Abstract][Full Text] [Related]
55. A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin.
Shepherd MH; Shields BM; Hudson M; Pearson ER; Hyde C; Ellard S; Hattersley AT; Patel KA;
Diabetologia; 2018 Dec; 61(12):2520-2527. PubMed ID: 30229274
[TBL] [Abstract][Full Text] [Related]
56. Analysis of the promoter regions of disease-causing genes in maturity-onset diabetes of the young patients.
Komazec J; Ristivojevic B; Zukic B; Zdravkovic V; Karan-Djurasevic T; Pavlovic S; Ugrin M
Mol Biol Rep; 2020 Sep; 47(9):6759-6768. PubMed ID: 32860162
[TBL] [Abstract][Full Text] [Related]
57. The spectrum of HNF1A gene mutations in Greek patients with MODY3: relative frequency and identification of seven novel germline mutations.
Tatsi C; Kanaka-Gantenbein C; Vazeou-Gerassimidi A; Chrysis D; Delis D; Tentolouris N; Dacou-Voutetakis C; Chrousos GP; Sertedaki A
Pediatr Diabetes; 2013 Nov; 14(7):526-34. PubMed ID: 23517481
[TBL] [Abstract][Full Text] [Related]
58. Should the negativity for islet cell autoantibodies be used in a prescreening for genetic testing in maturity-onset diabetes of the young? The case of autoimmunity-associated destruction of pancreatic β-cells in a family of HNF1A-MODY subjects.
Urbanová J; Rypáčková B; Kučera P; Anděl M; Heneberg P
Int Arch Allergy Immunol; 2013; 161(3):279-84. PubMed ID: 23548576
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis of hepatocellular adenoma in men before onset of diabetes in HNF1A-MODY: Watch out for winkers.
Haring MPD; Vriesendorp TM; Klein Wassink-Ruiter JS; de Haas RJ; Gouw ASH; de Meijer VE
Liver Int; 2019 Nov; 39(11):2042-2045. PubMed ID: 31483937
[TBL] [Abstract][Full Text] [Related]
60. High-sensitivity C-reactive protein does not improve the differential diagnosis of HNF1A-MODY and familial young-onset type 2 diabetes: A grey zone analysis.
Bellanné-Chantelot C; Coste J; Ciangura C; Fonfrède M; Saint-Martin C; Bouché C; Sonnet E; Valéro R; Lévy DJ; Dubois-Laforgue D; Timsit J;
Diabetes Metab; 2016 Feb; 42(1):33-7. PubMed ID: 25753245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
